Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
PASSENGERS and crew members of a British Airways flight who were taken hostage in Kuwait in 1990 are intending to take legal action against the British government and the airline, a law firm said Tuesday (12).
Passengers on BA flight 149 were taken off the Kuala Lumpur-bound plane when it landed in the Gulf state on August 2 that year, hours after Saddam Hussein's troops swept in.
Some of the 367 passengers and crew spent more than four months in captivity, including as human shields against western attacks at the hands of the Iraqi dictator.
Representing a group of former BA staff and passengers who were aboard the flight, McCue Jury & Partners said "the victims are taking legal action to ensure the truth is fully disclosed, those responsible are held to account, and due compensation is paid".
The law firm said that "what the hostages now know is that evidence exists" that the UK government and the airline "knew the invasion had already begun" but allowed the flight to land anyway.
And that they did so because "the flight was being used to insert a black ops team of former special forces and security services" into Kuwait, the firm added.
According to the law firm, the claim is currently at the pre-action stage and they expect to file the case early next year with the High Court in London.
The firm is appealing for more passengers or crew of the BA flight to join the legal action.
It said each of the hostages "may claim an estimated average of £170,000 ($213,000) each in damages".
"We were not treated as citizens, but as expendable pawns for commercial and political gain," Barry Manners, who was on the flight and is taking part in the claim, said.
"A victory over years of cover up and bare-faced denial will help restore trust in our political and judicial process," he added.
Files released in November 2021 revealed that the UK ambassador to Kuwait informed London about reports of an Iraqi incursion before the flight landed but the message was not circulated to BA.
There have also been claims, denied by the government, that London knowingly put passengers at risk by using the flight to deploy undercover operatives and delayed take-off to allow them to board.
A UK government spokesperson said "responsibility for these events and the mistreatment of those passengers and crew lies entirely with the government of Iraq at the time".
British Airways has always denied accusations of negligence, conspiracy and a cover-up.
A BA spokesperson said the government records released in 2021 "confirmed British Airways was not warned about the invasion".
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.